Verition Fund Management’s ImmunityBio IBRX Stock Holding History

Verition Fund Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.83M	Buy	+369,400	New	+$2.53M	0.02%	843

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Verition Fund Management's IBRX Position: Q1 2026 in Review

Verition Fund Management sold out of ImmunityBio (IBRX) in Q1 2026, closing a stake of 77,118 shares — an estimated $528K sold.

Verition Fund Management first reported a position in IBRX in Q1 2023 and held it in 9 quarters. The position peaked at $2.49M in Q1 2025. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Verition Fund Management reported no remaining ImmunityBio position as of Q1 2026 after selling out during the quarter.
Verition Fund Management sold 77,118 ImmunityBio shares in Q1 2026, an estimated $528K.
Verition Fund Management first reported a position in ImmunityBio in Q1 2023 and held it in 9 quarters.
Verition Fund Management's ImmunityBio position peaked at $2.49M in Q1 2025.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.